IL17C and neoplasm: Together, our data suggest that COPD-like inflammation associates with a tumor microenvironment that is required for an efficient anti-PD-1 therapy, but, at the same time, also promotes the expression of innate cytokines, such as IL-17C, that counteract the response to immune checkpoint inhibitors.